OK-432 is the pioneering work of researchers Hamao Okamoto and S. Koshimura.
Source: OK-432 (Picibanil) is derived from inactivated Streptococcus pyogenes.
Dual-Action: It acts as both a powerful activator of both native and adaptive immunity (a "biological response modifier") and a potent local sclerosant (causing localized tissue fusion/fibrosis).
Proof: It is a clinically proven, safe, and effective treatment for specific lymphatic malformations and various cancer types.
Snapshot


No comments:
Post a Comment